Connect with us

Business

CBD Shows Promise In Treating Epilepsy In Asian Population

Published

on

According to researchers, “CBD may be an effective option for Asian patients with refractory epilepsy, regardless of diagnosis or seizure type.”

A recently published Japanese study has yet again demonstrated CBD’s potential in epilepsy. This is the first study of this nature  to be conducted in the Asian population and has thus confirmed the benefits of CBD-based medications for treating severe forms of epilepsy.

The researchers administered questionnaires to 38 patients with intractable forms of epilepsy who were on CBD as a form of medication. The participants responded to questions regarding their demographics, medical history, diagnosis and type of seizure, CBD use,  and adverse events related to CBD use.

They also reported on changes observed after medicating on CBD such as seizure frequency and intensity, effect  on sleep, need for and dosage of supplemental anti-seizure medications, and quality of life. A total of 28 patients responded to the questionnaire.

medical cannabis
Photo by mikroman6/Getty Images

Promising Results for CBD Use in Epilepsy

The median intake for CBD was 12.0 mg/kg/day. Nine patients experienced some adverse effects, but they were mild and did not lead to discontinuation of the CBD treatment. Fifteen patients (over 50%) experienced a decrease in the frequency of seizures while two became seizure-free while taking CBD. No correlation was observed between the diagnosis or  type of seizure and the efficacy of the CBD treatment. The researchers hence concluded that:

According to researchers, “CBD may be an effective option for Asian patients with refractory epilepsy, regardless of diagnosis or seizure type.”

Here are a few things to note about intractable epilepsy and using CBD as a cure.

What Is Intractable Epilepsy?

Epilepsy is a disorder of the brain that is associated with frequent  seizures that occur when clusters of damaged neurons (brain cells) fire abnormal electric signals. This usually results in strong and uncontrollable muscle spasms that may result in loss of consciousness. Epileptic seizures are usually treated using antiepileptic drugs that  include sodium valproate, lamotrigine, and carbamazepine among others.

Unfortunately, these medications cause serious side effects when they are used for prolonged durations. As may be required of epilepsy patients. About 20% of epilepsies fail to respond to anti epilepsy medications and are hence referred to as refractory or intractable forms.

FDA Approves Epidiolex

In 2018, a drug known as Epidiolex was approved by the food and drug administration (FDA) to treat severe forms of drug-resistant epilepsy, specifically Dravet syndrome and Lennox Gastaut syndrome. This drug was created and patented by GW Pharmaceuticals and has been approved for the treatment of Lennox-Gastaut syndrome, Dravet’s syndrome, and seizures related to tuberous sclerosis complex.

CBD
Photo by Erin_Hinterland via Pixabay

CBD for Lennox-Gastaut syndrome

Lennox-Gastaut is a severe form of epilepsy that usually affects less than 5% of children. Some children suffering from this form of epilepsy experience up to 300 seizures in a day. Clinical trials have demonstrated the safety and efficacy of CBD in Lennox-Gastaut where drop seizures were reduced by 48%-71% while  total seizures were reduced by 48%-68%.

CBD for Dravet Syndrome

Dravets syndrome is a very rare type of intractable epilepsy that has been linked to a genetic mutation (SCN1A mutation). A 2017 trial demonstrated the suitability of CBD in managing  Dravet’s syndrome seizure attacks.

Does CBD for Seizures Cause Any Side Effects?

A majority of people, including children, are able to tolerate CBD quite well. When side effects are observed they are usually mild and do not necessitate discontinuation of CBD treatment. These include:

  • GI symptoms
  • Drowsiness
  • Diarrhea
  • Fatigue
  • Low appetite
  • Low blood pressure
medical marijuana
Photo by Visivasnc/Getty Images

What Is the Right Dosage of CBD for Epilepsy?

From clinical studies, it appears that a dosage of 5-6mg/kg/day is effective at managing severe seizure disorders in children. A physician may, however, choose to adjust the dosage accordingly, depending on the patient’s physiological characteristics, severity of the  seizures, and response to  treatment. The recommended Epidiolex dosage is 5mg/kg/day or 2.5mg/kg administered twice daily.

Does CBD Interact With Epilepsy Medications?

Yes, CBD interacts with some epilepsy medications including sodium valproate and clobazam. Before you start medicating on CBD, it is advisable to consult your pharmacist and let them advise you on a route that’s most suitable for you.

Source: https://thefreshtoast.com/cbd/cbd-shows-promise-in-treating-epilepsy-in-asian-population/

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News